Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide Roll-over Study
NCT01794793Phase 4Completed
- Sponsor
- Recordati SpA
- Start
- Jun 2013
- Primary completion
- Jul 2023
- Modality
- Peptides, Small Molecules
- Countries
- 28
01
Overview
A Phase 4 trial of pasireotide LAR in Cushing's disease (CD), acromegaly, Neuroendocrine Neoplasm (NEN), pituitary tumor, ectopic adrenocorticotropic hormone syndrome (EAS), sponsored by Recordati SpA. Started Jun 2013; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
Cushing's disease (CD)acromegalyNeuroendocrine Neoplasm (NEN)pituitary tumorectopic adrenocorticotropic hormone syndrome (EAS)
Beyond the preview
Go deeper on NCT01794793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01794793.